کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
2100607 1083012 2006 13 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Monoclonal antibody combinations in CLL: evolving strategies
موضوعات مرتبط
علوم زیستی و بیوفناوری بیوشیمی، ژنتیک و زیست شناسی مولکولی تحقیقات سرطان
پیش نمایش صفحه اول مقاله
Monoclonal antibody combinations in CLL: evolving strategies
چکیده انگلیسی

Monoclonal antibodies have led to a profound shift in the therapeutic landscape of chronic lymphocytic leukemia (CLL). Alemtuzumab and rituximab remain the most active antibodies, and their single-agent activity has been established in previously untreated and relapsed patients with CLL. Higher response rates and a better quality of response through eradication of minimal residual disease have been reported with monoclonal antibody combinations. Chemoimmunotherapy regimens are being actively explored in frontline CLL therapy, and numerous combination regimens have been investigated in relapse. New and more effective therapies are shifting the focus from palliation to treatment algorithms with curative attempt. Challenges for monoclonal antibody combinations in the future include: (1) defining appropriate patient populations for combination therapies; (2) assessing the impact of pretreatment biologic prognostic factors; (3) enhancing eradication of minimal residual disease; and (4) reassessing response criteria in CLL.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Best Practice & Research Clinical Haematology - Volume 19, Issue 4, December 2006, Pages 781–793
نویسندگان
, , ,